Company performance
Add to research
Current Price
as of Jun 18, 2025$2.11
P/E Ratio
4.25
Market Cap
$332.42M
Description
Add to research
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.
Metrics
Add to research
Overview
- HQSouth San Francisco, CA
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerCTMX
- Price$2.11-11.34%
Trading Information
- Market cap$332.42M
- Float66.19%
- Average Daily Volume (1m)3,271,665
- Average Daily Volume (3m)4,985,181
- EPS$0.50
Company
- Revenue$147.56M
- Rev growth (1yr)22.80%
- Net income$23.53M
- Gross margin99.24%
- EBITDA margin45.18%
- EBITDA$23.01M
- EV-$16.33M
- EV/Revenue-0.11
- P/E4.25
- P/S1.25
- P/B6.79
- Debt/Equity32.53
Documents
Add to research
SEC Filings
Factset Street Account
Earnings Calls
Factset